That's great. Thank you.
Therefore, the wording in this particular amendment, as I said previously, is related to contraception and diabetes, as my colleague Mr. Doherty has eloquently pointed out. It is clearly laid out in this bill that this is exactly what the pharmacare pamphlet is about. It is about the continuation of a national bulk purchasing strategy. It is not about creating something new.
You said there may be some forward-looking idea that at some time in the far future it could possibly change the vision of allowing the minister to ask the CDA for advice. I don't think that adding the words “continuation of a national bulk purchasing strategy” is going to harm in any way, shape, or form that potential or never-to-happen ability to ask the Canada drug agency for advice, because it now gets advice from the former arm, called CADTH, which we talked about. Part of its mandate as well is to talk about pharmacoeconomics and costs versus benefits.
I thank you again. In no way, shape, or form did I mean to be disparaging towards your answers, but I think it's important to seek clarity.
Chair, from the interventions that we have heard and the advice that we've obtained from our experts here this evening, it's even more important, on the basis of clarity and transparency for Canadians, to understand that the amendment proposed in CPC-9 is the appropriate amendment to bring clarity and vision to the pharmacare pamphlet.
Thank you, Chair, and thank you, Mr. MacDonald.